A critical review of pharmacotherapy for youth with anxiety disorders: things are not as they seem.
Given the increasing trend in clinical child psychology and psychiatry toward cost-effective and pharmacological treatment, a review of key factors that influence treatment outcomes in this area seems warranted. This is especially important for the rapidly changing area of childhood anxiety disorders. In this article, we look at different change producing procedures to illustrate the claim that pharmacological studies are not necessarily what they seem. Specifically, pharmacological outcome studies are classified and reviewed on the basis of varying "secondary" treatments described in method sections. Three groups and efficacy rates were determined: (a) pharmacotherapy only (42.83%), (b) pharmacotherapy plus general/supportive psychotherapy (27.74%), and (c) pharmacotherapy plus a behavior therapy component (65.28%). We also discuss the implications of these findings for research as well as other methodological and theoretical concerns regarding the reviewed articles. These concerns include (a) methods used to diagnose participants, (b) methods used to assess improvement, (c) emphasis on diagnostic categories, (d) exclusionary criteria and comorbidity, (e) participant attrition and follow-up, and (f) key developmental and social contextual variables.
Kearney
C A
CA
University of Nevada, Las Vegas 89154-5030, USA.
Silverman
W K
WK
D000293:Adolescent; D000296:Adolescent Psychiatry; D014151:Anti-Anxiety Agents / Q000191:economics / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002665:Child Psychiatry; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D011613:Psychotherapy; D012107:Research Design; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents